Literature DB >> 20538090

Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein.

Chunwei Shi1, Lingxia Chen, Zhenhua Chen, Ying Zhang, Zhiguang Zhou, Jia Lu, Ruiling Fu, Chun Wang, Zhengming Fang, Xionglin Fan.   

Abstract

Immunization with Mycobacterium bovis Bacille Calmette-Guerin (BCG) did not induce adequate Th1 responses to the latency antigen, HspX of M. tuberculosis. To increase the immunogenicity and protective efficacy of BCG, a recombinant BCG strain over-expressing antigen HspX (rBCG::X) was constructed. The recombinant strain rBCG::X expressed high levels of both HspX protein in the cytosol and Ag85B protein in the cytosol and supernatant. Mice vaccinated with rBCG::X produced a more consistent and enduring protective effect against infection with M. tuberculosis, showing lower bacterial load in lung and less severe lung pathology, than the control mice vaccinated with BCG strain containing the vector pMV261. The long-term protection induced by rBCG::X was associated with significant increases in antigen-specific IFN-gamma to both HspX and Ag85B proteins, while PPD-specific IFN-gamma responses declined. Our results suggest that latency antigens of M. tuberculosis may be promising targets for developing more effective recombinant BCG strains to protect against TB. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538090     DOI: 10.1016/j.vaccine.2010.05.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

2.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors:  Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

4.  Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.

Authors:  K F Siddiqui; M Amir; N Khan; G Rama Krishna; J A Sheikh; K Rajagopal; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

5.  Design and Construction of a Cloning Vector Containing the hspX Gene of Mycobacterium tuberculosis.

Authors:  Atieh Yaghoubi; Ehsan Aryan; Hosna Zare; Shadi Alami; Roghayeh Teimourpour; Zahra Meshkat
Journal:  Rep Biochem Mol Biol       Date:  2016-10

6.  A comparative approach to strategies for cloning, expression, and purification of Mycobacterium tuberculosis mycolyl transferase 85B and evaluation of immune responses in BALB/c mice.

Authors:  Haniyeh Aghababa; Ashraf Mohabati Mobarez; Nima Khoramabadi; Mehrdad Behmanesh; Mehdi Mahdavi; Majid Tebianian; Mehdi Nejati
Journal:  Mol Biotechnol       Date:  2014-06       Impact factor: 2.695

7.  A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.

Authors:  Chun Wang; Zhenhua Chen; Ruiling Fu; Ying Zhang; Lingxia Chen; Li Huang; Jinjin Li; Chunwei Shi; Xionglin Fan
Journal:  Med Microbiol Immunol       Date:  2011-02-22       Impact factor: 3.402

8.  HspX vaccination and role in virulence in the guinea pig model of tuberculosis.

Authors:  Agatha E Wieczorek; Jolynn L Troudt; Phillip Knabenbauer; Jennifer Taylor; Rebecca L Pavlicek; Russell Karls; Anne Hess; Rebecca M Davidson; Michael Strong; Helle Bielefeldt-Ohmann; Angelo A Izzo; Karen M Dobos
Journal:  Pathog Dis       Date:  2014-02-24       Impact factor: 3.166

9.  Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.

Authors:  In Duk Jung; Sung Jae Shin; Min-Goo Lee; Tae Heung Kang; Hee Dong Han; Seung Jun Lee; Woo Sik Kim; Hong Min Kim; Won Sun Park; Han Wool Kim; Cheol-Heui Yun; Eun Kyung Lee; T-C Wu; Yeong-Min Park
Journal:  J Immunol       Date:  2014-07-02       Impact factor: 5.422

10.  Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Authors:  Kun Tan; Jinping Liang; Xindong Teng; Xiaochun Wang; Jingyan Zhang; Xuefeng Yuan; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2013-11-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.